ASYMCHEM LAB.(TIAN.)H YC1 Net Assets
ASYMCHEM LAB.(TIAN.)H YC1 net assets. Based on the latest financial reports, ASYMCHEM LAB.(TIAN.)H YC1 (7K90) has net assets worth €17.96 Billion EUR (≈ $21.00 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€20.70 Billion ≈ $24.21 Billion USD) and total liabilities (€2.74 Billion ≈ $3.21 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 7K90 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €17.96 Billion |
| % of Total Assets | 86.75% |
| Annual Growth Rate | 8.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.32 |
Net Assets of ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)
Net assets of ASYMCHEM LAB.(TIAN.)H YC1 from 2021 to 2025. This chart illustrates how ASYMCHEM LAB.(TIAN.)H YC1's net assets have evolved over time, based on quarterly financial data. See ASYMCHEM LAB.(TIAN.)H YC1 balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)
The table below shows the annual net assets of ASYMCHEM LAB.(TIAN.)H YC1 from 2021 to 2025. For live market cap and overall valuation, see ASYMCHEM LAB.(TIAN.)H YC1 (7K90) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €17.65 Billion ≈ $20.63 Billion |
+4.65% |
| 2024-12-31 | €16.86 Billion ≈ $19.71 Billion |
-3.70% |
| 2023-12-31 | €17.51 Billion ≈ $20.47 Billion |
+11.56% |
| 2022-12-31 | €15.70 Billion ≈ $18.35 Billion |
+24.46% |
| 2021-12-31 | €12.61 Billion ≈ $14.74 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ASYMCHEM LAB.(TIAN.)H YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 178.1% over the analyzed period, indicating profitable operations and earnings retention.
ASYMCHEM LAB.(TIAN.)H YC1 Net Assets Breakdown (December 2025)
ASYMCHEM LAB.(TIAN.)H YC1 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €8.82 Billion | 49.99% |
| Other Components | €8.82 Billion | 50.01% |
| Total Equity | €17.64 Billion | 100.00% |
ASYMCHEM LAB.(TIAN.)H YC1 Competitors by Market Cap
The table below lists competitors of ASYMCHEM LAB.(TIAN.)H YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Luoyang Glass
SHG:600876
|
$377.51 Million |
|
Zhejiang Jinsheng New Materials Co
SHE:300849
|
$377.54 Million |
|
Dufu Tech Corp Bhd
KLSE:7233
|
$377.60 Million |
|
Kangxin New Materials Co Ltd
SHG:600076
|
$377.76 Million |
|
Keystone Technology Co Ltd
SHG:605588
|
$377.43 Million |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
$377.29 Million |
|
Shanghai Ailu Package Co. Ltd.
SHE:301062
|
$377.26 Million |
|
China Datang Corporation Renewable Power Co. Limited
STU:DT7
|
$377.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ASYMCHEM LAB.(TIAN.)H YC1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,845,385,169 to 17,635,098,689, a change of 789,713,520 (4.7%).
- Net income of 1,132,569,776 contributed positively to equity growth.
- Dividend payments of 395,066,122 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.13 Billion | +6.42% |
| Dividends Paid | €395.07 Million | -2.24% |
| Other Changes | €52.21 Million | +0.3% |
| Total Change | €- | 4.69% |
Book Value vs Market Value Analysis
This analysis compares ASYMCHEM LAB.(TIAN.)H YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.34x to 0.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €34.24 | €11.60 | x |
| 2022-12-31 | €42.29 | €11.60 | x |
| 2023-12-31 | €47.29 | €11.60 | x |
| 2024-12-31 | €45.81 | €11.60 | x |
| 2025-12-31 | €48.91 | €11.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ASYMCHEM LAB.(TIAN.)H YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.42%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.98%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.15x
- Recent ROE (6.42%) is below the historical average (10.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 8.48% | 23.05% | 0.31x | 1.20x | €-191.73 Million |
| 2022 | 21.10% | 32.19% | 0.56x | 1.17x | €1.74 Billion |
| 2023 | 12.98% | 28.99% | 0.40x | 1.13x | €520.84 Million |
| 2024 | 5.63% | 16.35% | 0.30x | 1.15x | €-735.59 Million |
| 2025 | 6.42% | 16.98% | 0.33x | 1.15x | €-630.94 Million |
Industry Comparison
This section compares ASYMCHEM LAB.(TIAN.)H YC1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $380,407,590
- Average return on equity (ROE) among peers: -34.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ASYMCHEM LAB.(TIAN.)H YC1 (7K90) | €17.96 Billion | 8.48% | 0.15x | $377.48 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-1.58 Million | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $144.67 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $696.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About ASYMCHEM LAB.(TIAN.)H YC1
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more